跳至主要内容
临床试验/NCT01647568
NCT01647568已完成不适用

Safety of Continuing Anti-platelet Agents During Colonoscopic Polypectomy: A Prospective Study

Dallas VA Medical Center1 个研究点 分布在 1 个国家目标入组 715 人开始时间: 2009年12月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
715
试验地点
1

研究概览

简要总结

At our VA hospital, in general, it is the policy of our GI lab to not stop our patients anti-platelet therapy whenever they see us for a routine colonoscopy. We do this because we believe the risk of stopping these sort of medications outweigh the risks of a complication from a colonoscopy.

Therefore, we are enrolling patients who are either on clopidogrel or prasugrel or not on any anti-platelet/anti-coagulant therapy that come to our GI lab routine colonoscopies. We perform the procedure just like we normally would and then follow-up with the patient 7 and 30 days after their procedure.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients presenting to the GI lab for elective colonoscopy

排除标准

  • Patients on Coumadin or other anti-coagulants
  • Patients with Inflammatory Bowel Disease

研究者

申办方类型
Fed
责任方
Principal Investigator
主要研究者

Linda A Feagins

Staff Gastroenterologist

Dallas VA Medical Center

研究点 (1)

Loading locations...

相似试验